Tranquis Therapeutics � TQS-621

Redwood, California-based Tranquis Therapeutics, is a clinical-stage biopharmaceutical company that is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. Their therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a more functional state by targeting master regulators of cell energy metabolism, such as PGC1α. TQS-621, Tranquis’s second candidate has started IND-enabling work and is expected to enter clinical development in the near future as of January 2023. This promising follow-on compound is slated to be studied in a number of non-orphan neurodegenerative and systemic diseases, including Parkinson’s disease, Alzheimer’s disease and more.